Class Action

Quincy Bioscience’s Prevagen Supplement

Class Action

Quincy Bioscience’s Prevagen Supplement

December 2020: The appeal was dismissed because the appellant failed to pay filing and docketing fees.

November 2020: A federal judge granted final approval of the settlement agreement. Later in November, an objector filed a Notice of Appeal regarding the decision to approve the settlement agreement.

October 2020: TINA.org filed an amicus curiae brief opposing the terms of the proposed settlement agreement as unfair to consumers. To read the brief or learn about the issues raised by TINA.org, click here.

July 2020: A federal judge preliminarily approved the settlement agreement. A final fairness hearing is scheduled for November 17, 2020.

June 2020: Plaintiffs moved for preliminary approval of a settlement agreement that would provide class members with a 30 percent cash refund of the company’s suggested retail price for Prevagen products. Class members with proof of purchase may receive a maximum award of $70 while class members without proof of purchase may receive a maximum award of $12. The company also agreed to stop marketing that Prevagen improves memory without adequate scientific evidence to support such claims or qualifying the advertising claim with a disclaimer. This settlement would resolve seven lawsuits: Collins, Engert, Karanthos, Racies, Spath, and Vanderwerff, as well as one state case Miloro v. Quincy Bioscience.

April 2019: The Spath case was transferred to a court in New York. (Case No. 19-cv-3521, S.D.N.Y.)

October 2018: The parties agreed to consolidate this case with Vanderwerff v. Quincy Bioscience (Case No. 17-cv-784, D.N.J.), which will be the lead case.

August 2018: A class-action lawsuit was filed against Quincy Bioscience for allegedly falsely marketing the supplement Prevagen as being clinically tested to improve memory within 90 days and support “healthy brain function, sharper mind, and clearer thinking” when, according to plaintiffs, the supplement has not been clinically tested and does not provide the advertised brain and memory benefits. (Spath et al v. Quincy Bioscience Holding Company, Inc. et al, Case No. 18-cv-12416, D.N.J.)

For more of TINA.org’s coverage of Prevagen, click here.


Legal Action

Prevagen

Prevagen

TINA.org investigated the marketing of Prevagen, a supplement aimed at people suffering from memory loss, and found that Quincy Bioscience — the marketer and manufacturer of Prevagen — deceptively claimed…


Class-Action Tracker

Prevagen Dietary Supplements

Class Action

Prevagen Dietary Supplements

December 2020: The appeal was dismissed because the appellant failed to pay filing and docketing fees. November 2020: A federal judge granted final approval of the settlement agreement. Later in…

Quincy Bioscience’s Prevagen

Class Action

Quincy Bioscience’s Prevagen

December 2020: The appeal was dismissed because the appellant failed to pay filing and docketing fees. November 2020: A federal judge granted final approval of the settlement agreement. Later in…

Prevagen Supplement

Class Action

Prevagen Supplement

December 2020: The appeal was dismissed because the appellant failed to pay filing and docketing fees. November 2020: A federal judge granted final approval of the settlement agreement. Later in…

Prevagen Products

Class Action

Prevagen Products

December 2020: The appeal was dismissed because the appellant failed to pay filing and docketing fees. November 2020: A federal judge granted final approval of the settlement agreement. Later in…

Prevagen Dietary Supplement

Class Action

Prevagen Dietary Supplement

December 2020: The appeal was dismissed because the appellant failed to pay filing and docketing fees. November 2020: A federal judge granted final approval of the settlement agreement. Later in…

Prevagen Supplements

Class Action

Prevagen Supplements

A false advertising class-action lawsuit against Quincy Bioscience was dismissed in June 2016. The complaint, which was originally filed in state court in March 2015 and transferred to federal court…


The Latest

Filters

Comment at FDA Public Meeting on Dietary Supplements

Blog

Comment at FDA Public Meeting on Dietary Supplements

Comment made by TINA.org executive director, Bonnie Patten at the FDA’s public meeting on Responsible Innovation in Dietary Supplements held on May 16, 2019. Thank you for the opportunity to…


Show More